Showing 2741-2750 of 3223 results for "".
- Pfizer, Moderna and J&J Tout Supercharged COVID-19 Vaccine Output, Eyeing Nearly 140 Million New Doses by Marchhttps://modernod.com/news/pfizer-moderna-and-jj-tout-supercharged-covid-19-vaccine-output-eyeing-nearly-140-million-new-doses-by-march/2478909/Pfizer, Moderna, and Johnson & Johnson execs say they’re working all the angles on increasing COVID-19 vaccine production and expect to amp up weekly deliveries by tens of millions by the end of March, according to a FiercePharma
- Optimo Medical and Ansys Partner Announce Partnership to Improve Surgery Preparationhttps://modernod.com/news/optimo-medical-and-ansys-partner-announce-partnership-to-improve-surgery-preparation/2478904/Optimo Medical and Ansys are incorporating high-fidelity structural simulations with digital twin technology into next-generation surgery preparation, according to a company news release. The collaboration also drives in silico clinical trials of new eye products, with the aim of significantly re
- Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operationshttps://modernod.com/news/bausch-health-to-reduce-debt-by-100-million-using-cash-generated-from-operations/2478894/Bausch Health announced it will reduce debt by $100 million through the redemption of outstanding senior secured notes, using cash generated from operations. “As Bausch Health continues its recovery from the effects of the COVID-19 pandemic, we also rema
- Single Dose of Pfizer, BioNTech’s COVID-19 Vaccine 85% Effective: Studyhttps://modernod.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/Study results published in The Lancet showed that a single dose of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 is 85% effective at preventing symptomatic disease 15 to 28 days after being administered. The data, which come from an analysis of healthcare workers in Israel, also
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- Real-World Use Analysis Backs Efficacy of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/real-world-use-analysis-backs-efficacy-of-pfizer-biontechs-covid-19-vaccine/2478875/Results from real-world use of Pfizer and BioNTech’s BNT162b2 show that two doses of the mRNA-based vaccine can cut the number of symptomatic COVID-19 infections by 94%, whilst also reducing severe illness by 92%. The Clalit Research Institute’s preliminary findings come from an analy
- Nicox’s US Licensee Eyevance Expands U.S. Promotion of Zerviate In Agreement with Hikmahttps://modernod.com/news/nicoxs-us-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma/2478867/Nicox announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of Zerviate, indicated for the treatment of ocular itching associated with allergic conjunc
- FDA Clears Lilly’s COVID-19 Antibody Duo Bamlanivimab, Etesevimab for Emergency Usehttps://modernod.com/news/fda-clears-lillys-covid-19-antibody-duo-bamlanivimab-etesevimab-for-emergency-use/2478854/Eli Lilly said Tuesday that it received FDA emergency-use authorization (EUA) for a neutralizing antibody cocktail combining bamlanivimab with etesevimab to treat mild-to-moderate COVID-19 in patients 12 and older who are at high risk for progressing to severe disease and/or hospitalization. Acco
- Focus Vitamins Unveils New Blue Light Product to Help Protect Eyes from Digital Devices and Eye Fatiguehttps://modernod.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/Covalent Medical, owner of the brand “Focus Vitamins,” announced today that their new Blue Light mango-flavored gummy will be available to their partner physician practices for resale. “The B.L.U.E. study shows using electronic digital devices can cause eye fatigue, and even interrupt slee
- jCyte Promotes Dr. Shannon Blalock to Chief Executive Officerhttps://modernod.com/news/jcyte-promotes-dr-shannon-blalock-to-chief-executive-officer/2478840/jCyte announced the Board of Directors has promoted Shannon Blalock, PharmD, to Chief Executive Officer, and an elected member of the Board. Dr. Blalock joined jCyte last year as its Chief Operating Officer. “I am thrilled to announce the appointment of Shannon as jCyte’s new CEO at this i